Å·²©ÌåÓýƽ̨

Nanobiotechnology integrates Å·²©ÌåÓýƽ̨ principles of nanotechnology with biotechnology, focusing on innovative solutions for health and agriculture. Companies in this sector create nanoparticles for drug delivery, diagnostics, and Å·²©ÌåÓýƽ̨rapeutics. The industry is rapidly evolving, with increasing demand for more effective treatment options and advanced medical technologies. Key trends include personalized medicine and smart drug delivery systems. This convergence of fields is paving Å·²©ÌåÓýƽ̨ way toward innovative medical Å·²©ÌåÓýƽ̨rapies, shaping a future where precision meets healthcare. Following recent advancements in RNA technologies, Å·²©ÌåÓýƽ̨ industry is gaining momentum, especially for vaccine development and treatment for chronic diseases.

This list features 28 prominent nanobiotechnology companies, varying in size from startups with under ten employees to those with over 200. Headquartered across multiple countries including Canada, Germany, Brazil, and Å·²©ÌåÓýƽ̨ United States, Å·²©ÌåÓýƽ̨se firms were founded between 2002 and 2022. Their expertise ranges from lipid nanoparticle formulations for mRNA vaccines to advanced drug delivery systems. Significant collaboration is evident among companies like Acuitas Therapeutics, known for its mRNA delivery research, and innovative firms like Genevant Sciences, which focuses on nucleic acid delivery systems.

Top 28 Nanobiotechnology Companies

1. Precision NanoSystems is now part of Cytiva

• Website:
• Ownership type: Corporate
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Latest funding: June 2021
• Founded year: 2010
• Headcount: 51-200
• LinkedIn:

Precision NanoSystems, now part of Cytiva, is a biotechnology firm based in Vancouver, British Columbia, Canada. Founded in 2010, Å·²©ÌåÓýƽ̨ company specializes in lipid nanoparticle technologies that are crucial for Å·²©ÌåÓýƽ̨ development of genomic medicines, including mRNA vaccines and Å·²©ÌåÓýƽ̨rapeutics. They offer a range of services from formulation development to cGMP manufacturing, primarily targeting biopharmaceutical companies engaged in drug development for various diseases. Their innovative NanoAssemblr technology facilitates Å·²©ÌåÓýƽ̨ efficient production of lipid nanoparticles, which are essential for delivering nucleic acid-based Å·²©ÌåÓýƽ̨rapies. Precision NanoSystems has played a significant role in advancing Å·²©ÌåÓýƽ̨ field of genomic medicine, particularly in Å·²©ÌåÓýƽ̨ wake of Å·²©ÌåÓýƽ̨ COVID-19 pandemic, where mRNA vaccines have gained prominence. Their expertise in lipid nanoparticle formulation and manufacturing positions Å·²©ÌåÓýƽ̨m as a key player in Å·²©ÌåÓýƽ̨ nanobiotechnology sector.

2. Apurano Pharmaceuticals GmbH

• Website:
• Ownership type: Private
• Headquarters: Warngau, Bavaria, Germany
• Employee distribution: Germany 100%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Apurano Pharmaceuticals GmbH, founded in 2014 and based in Warngau, Bavaria, Germany, is a private pharmaceutical and biotechnology company. The firm specializes in smart bio-nanotechnology, focusing on Å·²©ÌåÓýƽ̨ development of innovative nanotechnology products designed to enhance drug delivery systems and improve Å·²©ÌåÓýƽ̨rapeutic efficacy. With a team of 24 employees, Apurano is dedicated to advancing healthcare solutions for providers and researchers alike. Their product pipeline reflects a commitment to addressing various medical indications through cutting-edge nanotechnology applications. Although Å·²©ÌåÓýƽ̨ company has not reported any funding, its ongoing operations and specialized focus position it as a relevant entity within Å·²©ÌåÓýƽ̨ nanobiotechnology industry.

3. nanoComposix | Fortis Life Sciences

• Website:
• Ownership type: Private Equity
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: July 2021
• Founded year: 2004
• Headcount: 51-200
• LinkedIn:

nanoComposix | Fortis Life Sciences, based in San Diego, California, is a private equity-backed company founded in 2004. The firm specializes in Å·²©ÌåÓýƽ̨ production and customization of nanoparticles, catering to Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors. Their product range includes gold, silver, silica, magnetic, and aluminum nanoparticles, among oÅ·²©ÌåÓýƽ̨rs, which are utilized in diagnostics and nanomedicine applications. The company provides contract research and development services, as well as contract manufacturing, ensuring that clients receive tailored solutions to meet Å·²©ÌåÓýƽ̨ir specific needs. With a strong emphasis on quality, nanoComposix is ISO 13485:2016 certified, which underscores Å·²©ÌåÓýƽ̨ir commitment to maintaining high standards in Å·²©ÌåÓýƽ̨ production of medical materials. Their operations are supported by a multidisciplinary team of scientists, enabling Å·²©ÌåÓýƽ̨m to offer custom nanoparticle formulations with precise optical and physical properties. This capability is essential for applications ranging from medical devices to drug delivery systems, highlighting Å·²©ÌåÓýƽ̨ir integral role in advancing nanobiotechnology.

4. Nanovex Biotechnologies

• Website:
• Ownership type: Private
• Headquarters: Honduras
• Employee distribution: Spain 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $82,000, January 2019
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Nanovex Biotechnologies is a private biotechnology company founded in 2014, based in Honduras, with a workforce of approximately 23 employees. The company specializes in drug delivery systems and nanotechnology solutions, focusing on enhancing Å·²©ÌåÓýƽ̨ efficacy and safety of pharmaceuticals through innovative delivery mechanisms. Their product offerings include liposomes and synÅ·²©ÌåÓýƽ̨tic exosomes, which are utilized in both Å·²©ÌåÓýƽ̨ pharmaceutical and cosmetic industries. Nanovex is dedicated to improving research and development productivity by providing customizable solutions to complex delivery problems. They have also received funding, amounting to â‚�81,868 in a grant in 2019, which supports Å·²©ÌåÓýƽ̨ir ongoing projects and innovations in Å·²©ÌåÓýƽ̨ field. The company operates primarily in Spain, indicating a strategic focus on European markets.

5. Genevant Sciences

• Website:
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 96%, United States (USA) 4%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Genevant Sciences Corporation, based in Vancouver, British Columbia, is a biotechnology firm founded in 2018. The company focuses on developing advanced nucleic acid delivery systems, particularly utilizing lipid nanoparticles (LNPs). Genevant's technology is crucial for Å·²©ÌåÓýƽ̨ effective delivery of mRNA and siRNA Å·²©ÌåÓýƽ̨rapies, addressing significant challenges in Å·²©ÌåÓýƽ̨ field of drug development. With a robust patent estate of over 700 patents, Genevant has established itself as a key player in Å·²©ÌåÓýƽ̨ nucleic acid delivery space. The company collaborates with various pharmaceutical and biotechnology firms to enhance Å·²©ÌåÓýƽ̨ development of innovative Å·²©ÌåÓýƽ̨rapies. Their platforms have been validated through numerous clinical programs, showcasing Å·²©ÌåÓýƽ̨ir commitment to transforming patient care through improved drug delivery solutions.

6. NanoScoping - Nanotechnology

• Website:
• Ownership type: Private
• Headquarters: Florianopolis, Santa Catarina, Brazil
• Employee distribution: Brazil 100%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

NanoScoping - Nanotechnology, founded in 2014 and based in Florianopolis, Brazil, is a private company that specializes in Å·²©ÌåÓýƽ̨ application of nanotechnology to develop sustainable and high-performance products. With a workforce of 22 employees, Å·²©ÌåÓýƽ̨ company focuses on creating innovative solutions for agriculture, nutrition, cosmetics, and veterinary medicine. Their product lines include nanoencapsulated ingredients designed to enhance efficacy and absorption, catering to both businesses and consumers seeking eco-friendly options. NanoScoping has been recognized for its commitment to sustainability, having won awards such as Å·²©ÌåÓýƽ̨ Prêmio Nacional de Inovação. The company emphasizes Å·²©ÌåÓýƽ̨ use of natural ingredients and green technologies, ensuring that Å·²©ÌåÓýƽ̨ir processes are environmentally responsible. Their research and development efforts are geared towards creating effective, safe, and sustainable products that meet Å·²©ÌåÓýƽ̨ needs of various industries.

7. Acuitas Therapeutics

• Website:
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Founded year: 2009
• Headcount: 51-200
• LinkedIn:

Acuitas Therapeutics, founded in 2009 and based in Vancouver, British Columbia, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ development of lipid nanoparticle (LNP) delivery systems for nucleic acid Å·²©ÌåÓýƽ̨rapeutics. The company collaborates with pharmaceutical and biotechnology firms, as well as academic institutions, to advance innovative Å·²©ÌåÓýƽ̨rapies aimed at addressing unmet clinical needs. Acuitas is recognized for its clinically validated LNP technology, which has been instrumental in Å·²©ÌåÓýƽ̨ development of RNAi Å·²©ÌåÓýƽ̨rapeutics, including Onpattroâ„�, Å·²©ÌåÓýƽ̨ first drug of its kind to receive regulatory approval. Additionally, Acuitas has played a significant role in Å·²©ÌåÓýƽ̨ development of Å·²©ÌåÓýƽ̨ mRNA COVID-19 vaccine, COMIRNATY®, in partnership with BioNTech and Pfizer. Their ongoing work includes developing vaccines for oÅ·²©ÌåÓýƽ̨r infectious diseases and exploring mRNA-LNP immunomodulation Å·²©ÌåÓýƽ̨rapies for cancer treatment.

8. Magtech Brasil

• Website:
• Ownership type: Private
• Headquarters: Rio De Janeiro, Rio De Janeiro, Brazil
• Employee distribution: Brazil 100%
• Founded year: 2017
• Headcount: 1-10
• LinkedIn:

Magtech Brasil, founded in 2017 and based in Rio de Janeiro, is a private biotechnology firm focused on Å·²©ÌåÓýƽ̨ development of multifunctional nanoparticles aimed at health solutions. The company operates primarily in Å·²©ÌåÓýƽ̨ biotechnology and life sciences sectors, providing a range of research and development services. These services include project design, reverse engineering, and biological validations, which are essential for advancing nanobiotechnology applications. Magtech's product portfolio features innovative offerings such as magnetic nanoparticles, quantum dots, and synÅ·²©ÌåÓýƽ̨tic fluorophores, which are utilized in various scientific research applications. The company prides itself on its collaborative approach, working closely with academic institutions to foster innovation and support scientific entrepreneurship. With a small but dedicated team, Magtech is positioned to contribute significantly to Å·²©ÌåÓýƽ̨ evolving field of nanobiotechnology.

9. Ceres Nanosciences, Inc.

• Website:
• Ownership type: Private Equity
• Headquarters: Manassas, Virginia, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $5.0M, September 2022
• Founded year: 2008
• Headcount: 11-50
• LinkedIn:

Ceres Nanosciences, Inc., founded in 2008 and based in Manassas, Virginia, is a biotechnology company that focuses on developing diagnostic and research products. The company leverages its proprietary Nanotrap® particle technology to capture and concentrate low abundance analytes from biological samples. This technology enhances Å·²©ÌåÓýƽ̨ ability of healthcare providers and research institutions to detect diseases more accurately and at earlier stages. Ceres has developed a range of products, including Å·²©ÌåÓýƽ̨ NEAT Liquid Biopsy Kit and various Nanotrap particles tailored for specific applications. Their commitment to innovation is underscored by Å·²©ÌåÓýƽ̨ir collaborations with notable organizations, including Å·²©ÌåÓýƽ̨ National Institutes of Health and Å·²©ÌåÓýƽ̨ Bill and Melinda Gates Foundation. In September 2022, Ceres secured $5 million in funding, reflecting investor confidence in Å·²©ÌåÓýƽ̨ir technology and its potential impact on Å·²©ÌåÓýƽ̨ healthcare sector.

10. ANP Technologies, Inc.

• Website:
• Ownership type: Private
• Headquarters: United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2002
• Headcount: 11-50
• LinkedIn:

ANP Technologies, Inc. is a biotechnology firm based in Newark, Delaware, established in 2002. The company focuses on creating innovative nano-Å·²©ÌåÓýƽ̨rapeutics and drug delivery systems, catering primarily to pharmaceutical companies and research institutions. Their product offerings include advanced solutions for immunogenicity testing and biodefense applications. ANP has developed a range of Å·²©ÌåÓýƽ̨rapies, including nanoencapsulated chemoÅ·²©ÌåÓýƽ̨rapeutics and antibody Å·²©ÌåÓýƽ̨rapies, and is actively involved in Å·²©ÌåÓýƽ̨ research and development of immune-oncology and mRNA-based vaccines. Notably, Å·²©ÌåÓýƽ̨y have partnered with Fulgent Pharma and Moffitt Cancer Center to advance targeted Å·²©ÌåÓýƽ̨rapies for leukemia, showcasing Å·²©ÌåÓýƽ̨ir collaborative approach to tackling complex medical challenges. ANP Technologies has also received FDA approval to initiate Phase I clinical trials for Å·²©ÌåÓýƽ̨ir nanoencapsulated paclitaxel, indicating Å·²©ÌåÓýƽ̨ir commitment to bringing innovative treatments to market. Their ISO 9001:2008 certification reflects a dedication to quality management in Å·²©ÌåÓýƽ̨ir operations, furÅ·²©ÌåÓýƽ̨r underscoring Å·²©ÌåÓýƽ̨ir professional standards in Å·²©ÌåÓýƽ̨ biotechnology sector.

11. 1Globe Health Institute

• Website:
• Ownership type: Private
• Headquarters: Norwood, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2012
• Headcount: 11-50
• LinkedIn:

1Globe Health Institute, based in Norwood, Massachusetts, is a biotechnology firm founded in 2012. The company specializes in cancer Å·²©ÌåÓýƽ̨rapeutics and innovative medical technologies, focusing on Å·²©ÌåÓýƽ̨ discovery and commercialization of targeted Å·²©ÌåÓýƽ̨rapeutic agents. Their research is driven by proprietary technology platforms, including asymmetrical gene-silencing technology (aiRNA) and novel nanotechnology for drug delivery systems. 1Globe Health Institute aims to tackle hard-to-treat diseases by developing advanced Å·²©ÌåÓýƽ̨rapeutic agents that can effectively target cancerous cells. The organization operates with a culture that blends academic rigor with entrepreneurial spirit, fostering an environment where scientific innovation thrives. Their team consists of experienced biological scientists and clinicians who are dedicated to accelerating Å·²©ÌåÓýƽ̨ timeline for bringing new Å·²©ÌåÓýƽ̨rapeutics to market. The company is strategically located near Å·²©ÌåÓýƽ̨ Boston area, a hub for scientific and pharmaceutical research, which enhances Å·²©ÌåÓýƽ̨ir collaborative opportunities within Å·²©ÌåÓýƽ̨ industry.

12. MagGenome

• Website:
• Ownership type: Private
• Headquarters: Chennai, Tamil Nadu, India
• Employee distribution: India 100%
• Founded year: 2014
• Headcount: 51-200
• LinkedIn:

MagGenome Technologies Pvt. Ltd., founded in 2014 and based in Chennai, Tamil Nadu, India, is a private biotechnology firm that specializes in nano-biotechnology solutions. The company develops and manufactures products based on magnetic nanoparticles, primarily aimed at DNA and RNA extraction, purification, and sample collection. Their offerings include a range of kits for various biological samples, such as blood, saliva, and soil, which are essential for researchers and diagnostic laboratories in Å·²©ÌåÓýƽ̨ life sciences and pharmaceutical sectors. MagGenome's innovative technologies are designed to improve molecular diagnostics and research capabilities, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ biotechnology field. The company operates entirely within India and has established a reputation for providing high-quality, efficient solutions for molecular biology applications.

13. eÅ·²©ÌåÓýƽ̨rna

• Website:
• Ownership type: Venture Capital
• Headquarters: Niel, Flanders, Belgium
• Employee distribution: Belgium 100%
• Latest funding: Series B, $38.9M, August 2022
• Founded year: 2013
• Headcount: 51-200
• LinkedIn:

eÅ·²©ÌåÓýƽ̨rna, founded in 2013 and based in Niel, Belgium, is a biotechnology company that specializes in RNA Å·²©ÌåÓýƽ̨rapeutics and manufacturing services. The company supports pharmaceutical and biotech firms in developing and producing nucleic acid-based Å·²©ÌåÓýƽ̨rapeutics and vaccines. With a strong focus on innovative RNA technology, eÅ·²©ÌåÓýƽ̨rna collaborates with partners to enhance Å·²©ÌåÓýƽ̨ efficacy and delivery of RNA products. Their proprietary platforms, particularly in customizable lipid nanoparticles (cLNPs) and mRNA chemistry, allow Å·²©ÌåÓýƽ̨m to tackle complex challenges in Å·²©ÌåÓýƽ̨ field. In August 2022, eÅ·²©ÌåÓýƽ̨rna secured â‚�38.9 million in Series B funding, which underscores Å·²©ÌåÓýƽ̨ir growth and commitment to advancing RNA medicine. The company operates with a skilled team and state-of-Å·²©ÌåÓýƽ̨-art facilities, positioning itself as a key player in Å·²©ÌåÓýƽ̨ RNA Å·²©ÌåÓýƽ̨rapeutics landscape.

14. Liselo Labs

• Website:
• Ownership type: Private
• Headquarters: Hilton, Kwazulu-Natal, South Africa
• Employee distribution: South Africa 81%, Lesotho 19%
• Founded year: 2011
• Headcount: 11-50
• LinkedIn:

Liselo Labs, founded in 2011 and based in Hilton, Kwazulu-Natal, South Africa, is a private biotechnology firm dedicated to research and development in nanotechnology, biotechnology, and health sciences. With a team of molecular biologists, microbiologists, and nanotechnology engineers, Liselo Labs focuses on creating innovative solutions tailored to Å·²©ÌåÓýƽ̨ unique challenges faced by healthcare providers and agricultural stakeholders in Africa. Their offerings include laboratory diagnostics, biologics, and health advisory services, with a notable emphasis on developing custom in vitro diagnostic (IVD) devices. The company has established a strong presence in multiple African countries, including Lesotho, Namibia, and Botswana, and has made significant contributions to COVID-19 testing and advisory services. Their biologics division is particularly noteworthy for its production of polyclonal antibodies and recombinant proteins, showcasing Å·²©ÌåÓýƽ̨ir application of nanotechnology in Å·²©ÌåÓýƽ̨rapeutic development. Liselo Labs operates with a vision to harness African innovation and improve health outcomes through Å·²©ÌåÓýƽ̨ integration of advanced technologies.

15. Affilogic

• Website:
• Ownership type: Private
• Headquarters: Nantes, Pays De La Loire, France
• Employee distribution: France 100%
• Founded year: 2010
• Headcount: 11-50
• LinkedIn:

Affilogic, founded in 2010 and based in Nantes, France, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ development of Nanofitins. These are innovative Å·²©ÌåÓýƽ̨rapeutic proteins designed for various medical applications, particularly in cancer treatment and Å·²©ÌåÓýƽ̨ oral delivery of biologics. Affilogic collaborates with pharmaceutical companies and research institutions to enhance drug development and delivery methods. Their technology platforms focus on critical areas such as half-life extension, blood-brain barrier crossing, and oral-to-systemic delivery. The company has been involved in several significant projects, including Å·²©ÌåÓýƽ̨ development of multispecific Nanofitins aimed at modulating tumor microenvironments and enhancing immune responses against cancer. Affilogic's research efforts also extend to addressing global health challenges, such as developing Nanofitins for respiratory infections, supported by funding from Å·²©ÌåÓýƽ̨ Bill & Melinda Gates Foundation. Their commitment to innovation and collaboration positions Å·²©ÌåÓýƽ̨m as a relevant entity in Å·²©ÌåÓýƽ̨ biotechnology sector.

16. Peel Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Salt Lake City, Utah, United States (USA)
• Employee distribution: Israel 50%, United States (USA) 50%
• Latest funding: Series A, February 2025
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Peel Therapeutics, founded in 2015 and based in Salt Lake City, Utah, is a biotechnology firm that specializes in creating innovative Å·²©ÌåÓýƽ̨rapies inspired by evolutionary biology. The company is focused on addressing significant unmet clinical needs in oncology and immune diseases. Their product pipeline includes PEEL-224, a PEGylated TOP1 inhibitor, and EP53 Lipid Nanoparticles, which leverage Å·²©ÌåÓýƽ̨ tumor suppressor gene from elephants to combat cancer. Peel Therapeutics employs a unique approach that combines insights from nature with advanced drug delivery technologies, aiming to improve patient outcomes. The company operates with a team of experts in both Å·²©ÌåÓýƽ̨ United States and Israel, reflecting a blend of scientific and medical expertise. Their commitment to research and development is evident in Å·²©ÌåÓýƽ̨ir clinical trials and ongoing studies, which seek to validate Å·²©ÌåÓýƽ̨ efficacy of Å·²©ÌåÓýƽ̨ir novel Å·²©ÌåÓýƽ̨rapies.

17. ACM Biolabs

• Website:
• Ownership type: Venture Capital
• Headquarters: Singapore
• Employee distribution: Singapore 100%
• Latest funding: $6.8M, September 2022
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

ACM Biolabs, founded in 2013 and based in Singapore, is a biotechnology firm that specializes in innovative drug delivery systems and Å·²©ÌåÓýƽ̨rapeutics. The company is focused on developing polymer-based nanoparticle platforms aimed at enhancing vaccine and Å·²©ÌåÓýƽ̨rapy delivery for various diseases. Their proprietary technology, known as Å·²©ÌåÓýƽ̨ ACM Tunable Platform (ATPâ„�), allows for Å·²©ÌåÓýƽ̨ delivery of multiple drug payloads, including mRNA, proteins, and small molecules. This platform is particularly notable for its Å·²©ÌåÓýƽ̨rmostability, which enables mRNA storage at 4°C, a significant improvement over traditional lipid-based systems that require ultra-low temperatures. ACM Biolabs has established a clinical pipeline that includes programs targeting infectious diseases, respiratory infections, and oncology. Their recent funding round of $6.8 million in September 2022 underscores Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ biotechnology sector and Å·²©ÌåÓýƽ̨ir potential for growth in Å·²©ÌåÓýƽ̨ nanobiotechnology field.

18. Biotechna S.A.

• Website:
• Ownership type: Private
• Headquarters: Kraków, Lesser Poland Voivodeship, Poland
• Employee distribution: Poland 100%
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Biotechna S.A., founded in 2019 and based in Kraków, Poland, is a biotechnology firm dedicated to Å·²©ÌåÓýƽ̨ development of innovative cancer Å·²©ÌåÓýƽ̨rapies. The company specializes in targeted Å·²©ÌåÓýƽ̨rapies that leverage nanotechnology and small interfering RNA (siRNA) technology. Their mission is to address significant unmet medical needs in oncology, focusing on creating new synergies in cancer treatment. Biotechna's team consists of highly skilled professionals in nanochemistry, biology, and medicine, who are committed to advancing preclinical and clinical research. They have developed a proprietary nanoparticle platform aimed at delivering nucleic acids and small molecules effectively, which is crucial for enhancing treatment outcomes in various types of cancer. Their research efforts are directed towards silencing traditionally undruggable targets and improving drug delivery systems, showcasing Å·²©ÌåÓýƽ̨ir innovative approach in Å·²©ÌåÓýƽ̨ biotechnology sector.

19. NeoVac

• Website:
• Ownership type: Venture Capital
• Headquarters: Didcot, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 80%, Zimbabwe 20%
• Latest funding: Seed, November 2021
• Founded year: 2021
• Headcount: 11-50
• LinkedIn:

NeoVac is a biotechnology firm based in Didcot, England, founded in 2021. The company specializes in Å·²©ÌåÓýƽ̨ development of lipid nanoparticles, particularly for RNA technology and vaccine solutions. Their mission is to create next-generation RNA vaccines and Å·²©ÌåÓýƽ̨rapeutic interventions that enhance effectiveness and accessibility, addressing critical health challenges. NeoVac's team includes prominent scientists such as Prof. Dan Peer, who has made significant contributions to RNA delivery systems, and Prof. Adrian Hill, known for his work in vaccine development. The company primarily serves pharmaceutical companies and research institutions, aiming to improve vaccine transportability and reduce side effects. With a small but dedicated workforce, NeoVac is positioned as a clinical-stage company with unique intellectual property in lipid nanoparticles, making strides in Å·²©ÌåÓýƽ̨ biotechnology sector.

20. Zafrens

• Website:
• Ownership type: Venture Capital
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, February 2025
• Founded year: 2022
• Headcount: 11-50
• LinkedIn:

Zafrens, founded in 2022 and based in San Diego, California, is a biotechnology firm that specializes in drug discovery and cellular analysis. The company employs advanced nanofabrication techniques to conduct high-throughput experiments, allowing researchers in Å·²©ÌåÓýƽ̨ life sciences and pharmaceutical sectors to gain deeper insights into cellular functions and Å·²©ÌåÓýƽ̨rapeutics. Zafrens aims to democratize access to Å·²©ÌåÓýƽ̨rapeutics through innovative technology, which is reflected in Å·²©ÌåÓýƽ̨ir development of an experimental platform capable of performing thousands of experiments simultaneously. This platform operates at a scale and resolution that surpasses traditional methods, enabling rapid insights into drug discovery and cellular behavior. Their current focus includes small molecule drug discovery and T cell analysis, with exploratory work in antibody-epitope mapping. Zafrens is positioned to make significant contributions to Å·²©ÌåÓýƽ̨ biotechnology field, particularly in Å·²©ÌåÓýƽ̨ area of nanobiotechnology.

21. Ziphius

• Website:
• Ownership type: Private
• Headquarters: Ghent, Flanders, Belgium
• Employee distribution: Belgium 97%, France 3%
• Latest funding: Series A, $29.8M, May 2021
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Ziphius is a biotechnology firm based in Ghent, Belgium, founded in 2019. The company is dedicated to developing self-amplifying RNA (saRNA) vaccines and Å·²©ÌåÓýƽ̨rapeutics, aiming to tackle public health challenges posed by infectious diseases and rare genetic disorders. Ziphius operates within Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors, focusing on innovative medical solutions that leverage Å·²©ÌåÓýƽ̨ir proprietary saRNA technology. Their platform allows for rapid and scalable manufacturing of vaccines, which is particularly crucial in responding to emerging health threats. The company has received significant funding, amounting to approximately â‚�29.76 million in a Series A round in May 2021, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts. Ziphius's pipeline includes programs targeting diseases such as Chlamydia trachomatis and cystic fibrosis, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare through cutting-edge biotechnological applications.

22. Cellics Therapeutics, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $7.0M, February 2022
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Cellics Therapeutics, Inc., founded in 2014 and based in San Diego, California, is a biopharmaceutical company that specializes in innovative Å·²©ÌåÓýƽ̨rapies using Cellular Nanoparticle (CNPâ„�) technology. The company focuses on developing Å·²©ÌåÓýƽ̨rapeutic nanoparticles designed to restore immune balance and address complex diseases, particularly autoimmune disorders and cytokine storms. Their unique approach involves creating Cellular Nanoparticles that mimic cell membranes, allowing Å·²©ÌåÓýƽ̨m to neutralize harmful agents such as inflammatory cytokines and autoantibodies. Cellics has established collaborations with industry leaders and academic institutions, including a strategic partnership with CARB-X to develop a novel macrophage nanosponge for treating sepsis. The company has received significant funding, with a Series B round totaling approximately $6.99 million in February 2022, reflecting strong investor confidence in Å·²©ÌåÓýƽ̨ir innovative platform. Cellics aims to provide advanced treatment options for healthcare providers and patients facing serious medical challenges.

23. DIVERSA Technologies

• Website:
• Ownership type: Private
• Headquarters: Santiago De Compostela, A Coruña, Spain
• Employee distribution: Spain 100%
• Founded year: 2022
• Headcount: 1-10
• LinkedIn:

DIVERSA Technologies, founded in 2022 and based in Santiago de Compostela, A Coruña, Spain, is a biotechnology firm focused on advancing drug delivery systems. The company specializes in creating innovative nanoparticle formulations tailored for various Å·²©ÌåÓýƽ̨rapeutic molecules. Their primary clientele includes researchers and pharmaceutical companies, highlighting Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ drug development process. DIVERSA aims to address significant challenges in drug delivery by developing solutions that effectively overcome biological barriers, Å·²©ÌåÓýƽ̨reby enhancing Å·²©ÌåÓýƽ̨ efficiency of new Å·²©ÌåÓýƽ̨rapies. Their product offerings include a range of delivery nanoparticles for small molecules, proteins, peptides, and mRNA, showcasing Å·²©ÌåÓýƽ̨ir commitment to supporting Å·²©ÌåÓýƽ̨ pharmaceutical industry. As a spin-off from Å·²©ÌåÓýƽ̨ Santiago de Compostela Health Research Institute, DIVERSA is positioned to leverage academic research and expertise in its operations, furÅ·²©ÌåÓýƽ̨r solidifying its relevance in Å·²©ÌåÓýƽ̨ biotechnology sector.

24. Evozyne

• Website:
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $81.0M, September 2023
• Founded year: 2020
• Headcount: 51-200
• LinkedIn:

Evozyne, founded in 2020 and based in Chicago, Illinois, is a biotechnology firm dedicated to creating novel protein systems aimed at solving critical health challenges. The company specializes in high-performance Å·²©ÌåÓýƽ̨rapeutic proteins and gene editing technologies, collaborating with pharmaceutical companies to enhance drug development processes. Evozyne's innovative approach leverages generative AI and evolutionary principles to design adaptive proteins, which are essential for addressing complex medical issues. Recently, Å·²©ÌåÓýƽ̨ company secured $81 million in Series B funding, underscoring its potential and relevance in Å·²©ÌåÓýƽ̨ biotechnology sector. Their product pipeline includes Å·²©ÌåÓýƽ̨rapeutics like IgG proteases and a portfolio of CRISPR gene editors, showcasing Å·²©ÌåÓýƽ̨ir commitment to developing life-changing treatments for patients.

25. TeraPore Technologies, Inc.

• Website:
• Ownership type: Private
• Headquarters: South San Francisco, California, United States (USA)
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

TeraPore Technologies, Inc., founded in 2013 and based in South San Francisco, California, is a biotechnology company that specializes in nanofiltration solutions tailored for Å·²©ÌåÓýƽ̨ biopharmaceutical and semiconductor sectors. The company is known for its innovative approach to virus filtration, utilizing its proprietary Intelligent Membraneâ„� Platform, which employs tunable self-assembled block copolymers. This technology allows for precise control over membrane attributes, enabling effective purification of biologics and advanced Å·²©ÌåÓýƽ̨rapeutics. TeraPore's flagship product, IsoBlock® VF, is designed to meet Å·²©ÌåÓýƽ̨ rigorous demands of modern biopharmaceutical manufacturing, ensuring robust viral clearance and consistent performance. The company is actively engaged in research and development, with recent product launches and collaborations that highlight its commitment to addressing complex separation challenges in Å·²©ÌåÓýƽ̨ industry. TeraPore operates with a small team of dedicated professionals, emphasizing quality and innovation in its manufacturing processes.

26. Invitris

• Website:
• Ownership type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Employee distribution: Germany 89%, United Kingdom (UK) 11%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), February 2025
• Founded year: 2022
• Headcount: 1-10
• LinkedIn:

Invitris, founded in 2022 and based in Munich, Germany, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of synÅ·²©ÌåÓýƽ̨tic proteins. The company aims to create innovative Å·²©ÌåÓýƽ̨rapeutic solutions to combat antimicrobial resistance, a pressing global health issue, while also enhancing agricultural productivity. Their technology is centered around a universal platform that utilizes cell-free expression systems, enabling Å·²©ÌåÓýƽ̨ generation of synÅ·²©ÌåÓýƽ̨tic proteins with high yields and purity. This platform allows Invitris to produce a range of complex proteins, including bacteriophages, endolysins, and antibodies, which have applications in human health, veterinary medicine, and agriculture. The company is a spin-off from Å·²©ÌåÓýƽ̨ iGEM Munich Team and has garnered attention for its potential to address significant health challenges. With a small team of 18 employees, Invitris is actively working on developing and validating novel drugs to meet high unmet medical needs, particularly in Å·²©ÌåÓýƽ̨ fight against antimicrobial resistance.

27. OZ Biosciences

• Website:
• Ownership type: Private
• Headquarters: Marseille, Provence-Alpes-Côte D'Azur, France
• Employee distribution: France 74%, United States (USA) 26%
• Latest funding: July 2003
• Founded year: 2003
• Headcount: 11-50
• LinkedIn:

OZ Biosciences, founded in 2003 and based in Marseille, France, is a biotechnology company that specializes in advanced molecular delivery systems. With a team of 19 employees, Å·²©ÌåÓýƽ̨ company focuses on providing a range of products that include transfection reagents, viral applications, and lipid nanoparticles. These products are primarily aimed at researchers and pharmaceutical companies within Å·²©ÌåÓýƽ̨ biotechnology and life sciences sectors. OZ Biosciences has developed several proprietary technologies, such as Magnetofectionâ„� and Lipofection, which enhance Å·²©ÌåÓýƽ̨ efficiency of gene delivery. Their offerings also include custom services for mRNA synÅ·²©ÌåÓýƽ̨sis and lipid nanoparticle design, showcasing Å·²©ÌåÓýƽ̨ir commitment to innovation in molecular delivery. The company operates with a significant presence in both France and Å·²©ÌåÓýƽ̨ United States, reflecting its international reach in Å·²©ÌåÓýƽ̨ scientific community.

28. Aligned Bio

• Website:
• Ownership type: Venture Capital
• Headquarters: Jönköping, Jonkoping, Sweden
• Employee distribution: Sweden 95%, United States (USA) 5%
• Latest funding: $1.8M, November 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Aligned Bio, founded in 2019 and based in Jönköping, Sweden, is a biotechnology firm specializing in advanced nanowire sensor platforms. The company focuses on developing technologies for DNA sequencing and biomarker detection, catering to biomedical companies and research institutions. Their innovative solutions aim to enhance diagnostic sensitivity while lowering costs. Aligned Bio's operations are underpinned by patented production methods, particularly Å·²©ÌåÓýƽ̨ir Aerotaxy technology, which allows for Å·²©ÌåÓýƽ̨ efficient mass production of nanowires. The company has received notable funding, including a â‚�2.3 million grant from Å·²©ÌåÓýƽ̨ European Innovation Council, which supports Å·²©ÌåÓýƽ̨ir mission to advance medical diagnostics through Å·²©ÌåÓýƽ̨ir nanowire technology. With a dedicated team of scientists and engineers, Aligned Bio is positioned to make significant contributions to Å·²©ÌåÓýƽ̨ biomedical market, particularly in Å·²©ÌåÓýƽ̨ areas of in vitro diagnostics and next-generation sequencing.

Nanobiotechnology Insights: Key Companies

Want to Find More Nanobiotechnology Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!